rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: I) Rheumatoid arthritis patients that that met the 2010 ACR/EULAR RA classification criteria ii) Patients treated with abatacept under patients' doctor's decision and followed for at least 1 year. iii) Patients with data of anti-CCP antibody titer measured before starting abatacept treatment.
Exclusion criteria
Exclusion criteria: Patients who were considered not to be eligible for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients that achieved SDAI remission criteria at 52 weeks in rheumatoid arthritis patients with and without ACPA positivity treated with abatacept. | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression of joint destruction in rheumatoid arthritis patients with and without ACPA positivity treated with abatacept Safety profile of abatacept treatment in rheumatoid arthritis patients with and without pulmonary comorbidity. | — |
Countries
Japan
Contacts
Nagoya University Hospital Orthopaedic Surgery